ES2062310T3 - Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado. - Google Patents

Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.

Info

Publication number
ES2062310T3
ES2062310T3 ES90203064T ES90203064T ES2062310T3 ES 2062310 T3 ES2062310 T3 ES 2062310T3 ES 90203064 T ES90203064 T ES 90203064T ES 90203064 T ES90203064 T ES 90203064T ES 2062310 T3 ES2062310 T3 ES 2062310T3
Authority
ES
Spain
Prior art keywords
procedure
manufacturing
stabilized
methionine
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90203064T
Other languages
English (en)
Inventor
Den Oetelaar Petrus Johann Van
Maria Martina Francisc Mentink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2062310T3 publication Critical patent/ES2062310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Abstract

SE PRESENTAN PREPARACIONES ACUOSAS ESTABILIZADAS QUE CONTIENEN UN ANTIDEPRESIVO EN UNA MEZCLA CON COMPUESTO ESTABILIZANTES TALES COMO LA L-METIONINA, D-METIONINA O MEZCLAS DE ESTAS. LAS PREPARACIONES ESTABILIZADAS OFRECEN UNA MEJOR ESTABILIDAD CUANDO SE EXPONEN A LA LUZ, A TEMPERATURAS RELATIVAMENTE ALTAS, AL TIEMPO Y A LOS PEROXIDOS QUE OFRECEN UNA MAYOR DURACION DE ALMACENAMIENTO. LOS ANTIDEPRESIVOS ESTABILIZADOS INCLUYEN LA MIRTAZAPINA, LA MIANSAINA, LA SEPTILINA Y LA AMITRIPTILINA.
ES90203064T 1989-12-06 1990-11-20 Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado. Expired - Lifetime ES2062310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89203092 1989-12-06

Publications (1)

Publication Number Publication Date
ES2062310T3 true ES2062310T3 (es) 1994-12-16

Family

ID=8202518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90203064T Expired - Lifetime ES2062310T3 (es) 1989-12-06 1990-11-20 Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.

Country Status (15)

Country Link
US (1) US5082864A (es)
EP (1) EP0431663B1 (es)
JP (1) JP2977912B2 (es)
KR (1) KR0185377B1 (es)
AT (1) ATE99943T1 (es)
AU (1) AU628768B2 (es)
CA (1) CA2030773C (es)
DE (1) DE69005992T2 (es)
DK (1) DK0431663T3 (es)
ES (1) ES2062310T3 (es)
FI (1) FI97689C (es)
IE (1) IE63985B1 (es)
NZ (1) NZ236332A (es)
PT (1) PT96096B (es)
ZA (1) ZA909568B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1591H (en) * 1992-10-09 1996-09-03 Fulcher; John Preparation of flavor-enhanced reduced calorie fried foods
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
DE69913116T2 (de) * 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ATE380884T1 (de) * 2001-02-12 2007-12-15 Organon Nv Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DK1617832T3 (da) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Præparater til påvirkning af vægttab
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
AU2007207606A1 (en) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for CNS conditions
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
EP2303025A4 (en) * 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
BR112012016783A2 (pt) * 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
KR101652081B1 (ko) 2014-12-30 2016-08-30 김인호 전극보일러 급탕시스템
HUE055000T2 (hu) 2015-02-27 2021-10-28 Dechra Ltd Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében
KR20170001494A (ko) 2015-06-26 2017-01-04 김인호 전극보일러 전류제어시스템
CN108853042B (zh) * 2018-09-20 2021-03-26 北京哈三联科技有限责任公司 一种米氮平冻干口崩片及其制备方法和应用
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
DE3247676A1 (de) * 1982-12-23 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Galenische form fuer amitriptylinoxid und verfahren zur herstellung

Also Published As

Publication number Publication date
FI97689C (fi) 1997-02-10
DE69005992D1 (de) 1994-02-24
CA2030773A1 (en) 1991-06-07
JPH05262651A (ja) 1993-10-12
CA2030773C (en) 2001-07-24
DE69005992T2 (de) 1994-05-05
ATE99943T1 (de) 1994-01-15
FI97689B (fi) 1996-10-31
ZA909568B (en) 1991-09-25
KR910011250A (ko) 1991-08-07
AU628768B2 (en) 1992-09-17
NZ236332A (en) 1992-07-28
PT96096A (pt) 1991-09-30
DK0431663T3 (da) 1994-03-07
JP2977912B2 (ja) 1999-11-15
IE904226A1 (en) 1991-06-19
AU6779890A (en) 1991-06-13
US5082864A (en) 1992-01-21
EP0431663A1 (en) 1991-06-12
EP0431663B1 (en) 1994-01-12
KR0185377B1 (ko) 1999-05-01
PT96096B (pt) 1998-02-27
FI906008A0 (fi) 1990-12-05
IE63985B1 (en) 1995-06-28
FI906008A (fi) 1991-06-07

Similar Documents

Publication Publication Date Title
ES2062310T3 (es) Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
IS3156A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
DK0675717T3 (da) Anvendelse af 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol (pramipexol) som lægemiddel med antidepressiv virknin
FI860842A (fi) Labdan-derivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
ES2059869T3 (es) Preparado farmaceutico que contiene piroxicam para uso topico.
ES2100263T3 (es) Nuevas isohirudinas sinteticas con estabilidad mejorada.
SE7514294L (sv) 4,4'-bis-/2",4"-bis-(diisopropanolamino)-s-triazin-6"-ylamino/-stilben-2,2'-disulfonsyra, dess framstellning och dess anvendning som optiskt vithetsforhojande medel
DK116687D0 (da) Farmaceutisk praeparat indeholdende aenovantroneae
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
DK11089A (da) 2,5-diazabicyclooe2.2.1aaheptan-forbindelser, deres anvendelse til fremstilling af antiarytmi-laegemidler, farmaceutiske praeparater indeholdende forbindelserne samt forbindelse til anvendelse som udgangsmateriale ved deres fremstilling
DK0457215T3 (da) 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf
MX9202987A (es) Analogos de insulina, formulacion farmaceutica que los contiene y procedimiento para obtener dichos analogos.
NO904961D0 (no) Glutarsyrederivater, samt fremstilling derav.
SE8503513D0 (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
SV2004001441A (es) Compuestos de isocromano ref. x-14205
DK104691A (da) Cykliske imidatestere til anvendelse som udgangsmateriale ved fremstillling af 1,4-dihydropyrid-5-yl-(cyklisk imidat)estere
DK0925785T3 (da) Stabiliseret farmaceutisk præparat indeholdende dopamin eller dobutamin
DK98788D0 (da) Benzylaminoaryl-dihydropyridinlactoner, fremgangmsaade til deres fremstilling samt deres anvendelse som laegemidler
DE69002027D1 (de) (3-diethylaminopropyl)-1-amino-5-methyldipyrido(4,3-b)(3,4-f)indoltrihydrochlorid.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 431663

Country of ref document: ES